Back to Search
Start Over
Early administration of IL-6RA does not prevent radiation-induced lung injury in mice.
- Source :
-
Radiation Oncology . 2010, Vol. 5, p26-31. 6p. - Publication Year :
- 2010
-
Abstract
- Background: Radiation pneumonia and subsequent radiation lung fibrosis are major dose-limiting complications for patients undergoing thoracic radiotherapy. Interleukin-6 (IL-6) is a pleiotropic cytokine and plays important roles in the regulation of immune response and inflammation. The purpose of this study was to investigate whether anti-IL-6 monoclonal receptor antibody (IL-6RA) could ameliorate radiation-induced lung injury in mice. Methods: BALB/cAnNCrj mice having received thoracic irradiation of 21 Gy were injected intraperitoneally with IL-6RA (MR16-1) or control rat IgG twice, immediately and seven days after irradiation. Enzyme-linked immunosorbent assay was used to examine the plasma level of IL-6 and serum amyloid A (SAA). Lung injury was assessed by histological staining with haematoxylin and eosin or Azan, measuring lung weight, and hydroxyproline. Results: The mice treated with IL-6RA did not survive significantly longer than the rat IgG control. We observed marked up-regulation of IL-6 in mice treated with IL-6RA 150 days after irradiation, whereas IL-6RA temporarily suppressed early radiation-induced increase in the IL-6 release level. Histopathologic assessment showed no differences in lung section or lung weight between mice treated with IL-6RA and control. Conclusions: Our findings suggest that early treatment with IL-6RA after irradiation alone does not protect against radiation-induced lung injury. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 1748717X
- Volume :
- 5
- Database :
- Academic Search Index
- Journal :
- Radiation Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 51104787
- Full Text :
- https://doi.org/10.1186/1748-717X-5-26